Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Tarun Garg

TitleAssistant Research Professor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentInternal Med, College of Medicine
DivisionInternal Med Hem-Onc
Address9-115 Cancer Institute
4104 Outpatient Circle
Mail Slot # 776
Little Rock AR 72205
Phone501-526-6990 x8482
ORCID ORCID Icon0000-0003-1948-0617 Additional info
vCardDownload vCard

    Collapse Research 
    Collapse research overview
    My research is focus on developing natural killer (NK) cells for immunotherapeutic use against multiple myeloma, which has poor outcome despite novel therapeutic agents. In addition, elucidation of resistance mechanisms in myeloma is another area of my interest. Myeloma cells has the ability to evade immune surveillance through several potential mechanisms. Exploration of these mechanisms may lead to develop better therapeutic option in multiple myeloma.

    Collapse research activities and funding
    2R01 HL 141408-06     (VAN RHEE, FRITS)Sep 1, 2023 - May 31, 2024
    NIH/Nat. Heart, Lung & Blood Institute - Pass Through: University of Pennsylvania
    JAK1/2 as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic Target
    Role: Principal Investigator
    W81XWH2110601     (YACCOBY, SHMUEL)Sep 30, 2021 - Sep 29, 2025
    US Department of Defense
    Role of novel myeloma subpopulations in the disease progression and drug resistance
    Role: Principal Investigator
    P20GM109005     (BOERMA, MARJAN)Jun 24, 2015 - May 31, 2025
    NIH
    Center for Studies of Host Response to Cancer Therapy
    Role: Co-Investigator
    4815     (GARG, TARUN)Jan 1, 2015 - Apr 30, 2016
    International Myeloma Foundation
    Multiple Myeloma Cells Modulate ICAM-3 to Evade Natural Killer Cell-Mediated Lysis
    Role: Principal Investigator
    4815-3004-4449     (GARG, TARUN K)Jan 1, 2015 - Apr 30, 2016
    International Myeloma Foundation
    Multiple Myeloma Cells Modulate ICAM-3 to Evade Natural Killer Cell-Mediated Lysis
    Role: Principal Investigator
    R01CA134522     (VAN RHEE, FRITS)Aug 22, 2008 - Jun 30, 2014
    NIH
    Potentiating Natural Killer Cell Anti-Myeloma Effects
    Role: Co-Investigator
    28-06     (VAN RHEE, FRITS)Oct 1, 2006 - Sep 30, 2008
    Multiple Myeloma Research Foundation
    KIR-Ligand Mismatched Natural Killer Cell Therapy for Myeloma
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Garg TK, Garg S, Miousse IR, Wise SY, Carpenter AD, Fatanmi OO, van Rhee F, Singh VK, Hauer-Jensen M. Modulation of Hematopoietic Injury by a Promising Radioprotector, Gamma-Tocotrienol, in Rhesus Macaques Exposed to Partial-Body Radiation. Radiat Res. 2024 01 01; 201(1):55-70. PMID: 38059553.
      View in: PubMed
    2. Das S, Chander R, Garg T, Mendiratta V, Singh R, Sanke S. Cardiovascular risk markers in premature canities. Indian J Dermatol Venereol Leprol. 2023 Jan-Mar; 89(2):221-225. PMID: 35841351.
      View in: PubMed
    3. Garg TK, Garg S, Miousse IR, Wise SY, Carpenter AD, Fatanmi OO, van Rhee F, Singh VK, Hauer-Jensen M. Gamma-Tocotrienol Modulates Total-Body Irradiation-Induced Hematopoietic Injury in a Nonhuman Primate Model. Int J Mol Sci. 2022 Dec 18; 23(24). PMID: 36555814.
      View in: PubMed
    4. Garg S, Garg TK, Miousse IR, Wise SY, Fatanmi OO, Savenka AV, Basnakian AG, Singh VK, Hauer-Jensen M. Effects of Gamma-Tocotrienol on Partial-Body Irradiation-Induced Intestinal Injury in a Nonhuman Primate Model. Antioxidants (Basel). 2022 Sep 25; 11(10). PMID: 36290618.
      View in: PubMed
    5. Gai D, Chen JR, Stewart JP, Nookaew I, Habelhah H, Ashby C, Sun F, Cheng Y, Li C, Xu H, Peng B, Garg TK, Schinke C, Thanendrarajan S, Zangari M, Chen F, Barlogie B, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. J Clin Invest. 2022 09 15; 132(18). PMID: 35881476.
      View in: PubMed
    6. Garg S, Garg TK, Wise SY, Fatanmi OO, Miousse IR, Savenka AV, Basnakian AG, Singh VK, Hauer-Jensen M. Effects of Gamma-Tocotrienol on Intestinal Injury in a GI-Specific Acute Radiation Syndrome Model in Nonhuman Primate. Int J Mol Sci. 2022 Apr 22; 23(9). PMID: 35563033.
      View in: PubMed
    7. Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, Yaccoby S, Waheed S, Gee A, Cottler-Fox M, Rooney C, Barlogie B, van Rhee F. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother. 2015 Jan; 38(1):24-36. PMID: 25415285.
      View in: PubMed
    8. Papanikolaou X, Johnson S, Garg T, Tian E, Tytarenko R, Zhang Q, Stein C, Barlogie B, Epstein J, Heuck C. Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis. Oncotarget. 2014 Jun 30; 5(12):4118-28. PMID: 24948357.
      View in: PubMed
    9. Stone K, Woods E, Szmania SM, Stephens OW, Garg TK, Barlogie B, Shaughnessy JD, Hall B, Reddy M, Hoering A, Hansen E, van Rhee F. Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels. PLoS One. 2013; 8(1):e54610. PMID: 23372742.
      View in: PubMed
    10. Lapteva N, Durett AG, Sun J, Rollins LA, Huye LL, Fang J, Dandekar V, Mei Z, Jackson K, Vera J, Ando J, Ngo MC, Coustan-Smith E, Campana D, Szmania S, Garg T, Moreno-Bost A, Vanrhee F, Gee AP, Rooney CM. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy. 2012 Oct; 14(9):1131-43. PMID: 22900959.
      View in: PubMed
    11. Garg TK, Szmania SM, Khan JA, Hoering A, Malbrough PA, Moreno-Bost A, Greenway AD, Lingo JD, Li X, Yaccoby S, Suva LJ, Storrie B, Tricot G, Campana D, Shaughnessy JD, Nair BP, Bellamy WT, Epstein J, Barlogie B, van Rhee F. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica. 2012 Sep; 97(9):1348-56. PMID: 22419581.
      View in: PubMed
    12. Moreno-Bost A, Szmania S, Stone K, Garg T, Hoerring A, Szymonifka J, Shaughnessy J, Barlogie B, Prentice HG, van Rhee F. Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103. Cytotherapy. 2011 May; 13(5):618-28. PMID: 21171821.
      View in: PubMed
    13. van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R, Balasa B, Ganguly B, Chao D, Rice AG, Zhan F, Shaughnessy JD, Barlogie B, Yaccoby S, Afar DE. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009 Sep; 8(9):2616-24. PMID: 19723891.
      View in: PubMed
    14. Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, Moreno A, Dupont B, Hsu KC, Baxter-Lowe LA, Cottler-Fox M, Shaughnessy JD, Barlogie B, van Rhee F. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol. 2008 Dec; 143(5):641-53. PMID: 18950462.
      View in: PubMed
    15. Kane CJ, Chang JY, Roberson PK, Garg TK, Han L. Ethanol exposure of neonatal rats does not increase biomarkers of oxidative stress in isolated cerebellar granule neurons. Alcohol. 2008 Feb; 42(1):29-36. PMID: 18249267.
      View in: PubMed
    16. Shi J, Tricot GJ, Garg TK, Malaviarachchi PA, Szmania SM, Kellum RE, Storrie B, Mulder A, Shaughnessy JD, Barlogie B, van Rhee F. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood. 2008 Feb 01; 111(3):1309-17. PMID: 17947507.
      View in: PubMed
    17. Garg TK, Chang JY. Methylmercury causes oxidative stress and cytotoxicity in microglia: attenuation by 15-deoxy-delta 12, 14-prostaglandin J2. J Neuroimmunol. 2006 Feb; 171(1-2):17-28. PMID: 16225932.
      View in: PubMed
    18. Agrawal N, You H, Liu Y, Chiriva-Internati M, Bremner J, Garg T, Grizzi F, Krishna Prasad C, Mehta JL, Hermonat PL. Generation of recombinant skin in vitro by adeno-associated virus type 2 vector transduction. Tissue Eng. 2004 Nov-Dec; 10(11-12):1707-15. PMID: 15684679.
      View in: PubMed
    19. Garg TK, Chang JY. 15-deoxy-delta 12, 14-Prostaglandin J2 prevents reactive oxygen species generation and mitochondrial membrane depolarization induced by oxidative stress. BMC Pharmacol. 2004 May 18; 4:6. PMID: 15149553.
      View in: PubMed
    20. Garg TK, Chang JY. Oxidative stress causes ERK phosphorylation and cell death in cultured retinal pigment epithelium: prevention of cell death by AG126 and 15-deoxy-delta 12, 14-PGJ2. BMC Ophthalmol. 2003 Mar 21; 3:5. PMID: 12659653.
      View in: PubMed
    21. Sood A, Sharma VK, Garg T, Nair M, Dinda AK. Amyloidosis in Reiter's syndrome. J Assoc Physicians India. 2001 May; 49:563-5. PMID: 11361274.
      View in: PubMed
    Garg's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (162) concept(s)
    _
    Co-Authors Expand Description
    See all (17) people
    _
    Similar People Expand Description
    See all (35) people
    _
    Same Department Expand Description
    Search Department